Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viekira Pak ± Ribavirin in Genotype 1 Chronic Hepatitis C (TOPAZ III)
NCT02442271Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of Viekira Pak in chronic hepatitis C virus infection (CHC), sponsored by AbbVie Inc.. Started Apr 2015; status: completed.
02
Drugs
Viekira Pak
03
Conditions
chronic hepatitis C virus infection (CHC)
Beyond the preview
Go deeper on NCT02442271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442271.